Contact

Anuma Home About Services Evidence Review Safety & Risks FAQs for Patients Contact Evidence, uncertainty & safety Ibogaine For Anxiety: Myths And What Is Known A careful look at a promising investigational signal, the limits of the evidence, and why cardiac safety—not marketing—must shape any discussion. Start with the evidence 01 Recognition 02 Evidence 03 Mechanisms 04 Safety 05 Decisions 01 · Recognition Why the question deserves a careful answer Ibogaine is not an FDA-approved treatment for anxiety, and there is no high-quality evidence establishing it as a stand-alone anxiolytic. Small, uncontrolled studies—especially in military veterans with traumatic brain injury and PTSD—have reported reductions in anxiety symptoms, but those findings remain preliminary. People considering ibogaine for anxiety may be looking for relief from persistent fear response, sleep disruption, panic, or the strain of co-occurring mental health conditions. That need is real. It does not turn an investigational psychedelic drug into a proven treatment for anxiety disorders. A recent overview of ibogaine treatment reflects a wider public conversation, but attention is not the same as evidence. The most defensible position is that research suggests a signal worth studying, while the known risks make unsupervised self-treatment unacceptable. The key distinction: anxiety reduction after ibogaine treatment for a substance use disorder is not evidence that ibogaine treats primary anxiety disorders. Most clinical studies have focused on addiction treatment, not representative patients with generalized anxiety disorder. For a broader map of what this independent resource covers, see the principles behind Anuma’s evidence-first approach . The purpose is clarity: what is known, what is uncertain, and what should not be promised. 02 · Context Understanding ibogaine Ibogaine is an indole alkaloid derived from the root bark of the Tabernanthe iboga plant. This iboga plant has a Gabonese ori

Contact

A careful place for feedback.